Galectin Therapeutics (FRA:PHPN) ROCE % : -299.79% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Galectin Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -299.79%.

Galectin Therapeutics ROCE % Historical Data

The historical data trend for Galectin Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics ROCE % Chart

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-50.42

-63.03

-108.69

-193.46

-363.81

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-480.82	-519.19	-357.82	-355.02	-299.79

Galectin Therapeutics ROCE % Calculation

Galectin Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-35.097	/	( ( (20.093 - 12.283)	+	(25.859 - 14.375) )	/ 2 )
	=	-35.097	/	( (7.81	+	11.484)	/ 2 )
	=	-35.097	/	9.647
	=	-363.81 %

Galectin Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-33.564	/	( ( (20.767 - 9.859)	+	(25.859 - 14.375) )	/ 2 )
	=	-33.564	/	( ( 10.908	+	11.484 )	/ 2 )
	=	-33.564	/	11.196
	=	-299.79 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Galectin Therapeutics (FRA:PHPN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Galectin Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (FRA:PHPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GALT:USA

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines